enrolment – Page 8 – Communicable Diseases Research

Assessing the safety of home oximetry for COVID-19: a multisite retrospective observational study

Observational Study

Published on 2021-09-142022-10-04
Journal: BMJ Open [Category] Fulltext, SARS, 임상,

The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic

Randomized Controlled Trial

Published on 2021-09-072022-10-04
Journal: Trials [Category] SARS, 임상,

[키워드] 6-lead ECG Accuracy adverse event approach approval cause clinical clinical trial Community concern COVID-19 COVID-19 disease COVID-19 infection COVID-19 pandemic determine develop diagnostic diagnostic tests ECG effective Efficacy eligible enrolled enrolment ethical committee exclusion exclusion criteria flexibility group groups HCQ health system Healthcare systems Hydroxychloroquine Inclusion individual infection control infection rate Internet lack measure medication methodology number observation Open-label organism outbreak pandemic PCR physical contact Population prevention of COVID-19 Prophylaxis Prospective clinical trial protocol Randomized recruitment Remote ECG monitoring remote monitoring Research researcher resource respond Result RNA Saliva SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 test Spread strained Treatment Trial Trial management USA World Health Organization
[DOI] 10.1186/s13063-021-05537-6 PMC 바로가기 [Article Type] Randomized Controlled Trial

Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial

중년의 중등도 증상 환자에서 아연과 시너지 효과를 나타내는 피하 이버멕틴의 항-COVID 특성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-09-062022-09-10
Journal: Trials [Category] SARS, 임상,

[키워드] 30-Day mortality absence activities approved Arm blinded calculated Chest clinic clinical co-morbidities co-morbidity comparator coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 symptom Data collection death dissemination doctor ECMO Effectiveness element Endpoint enrolment Evidence evidence of excluded FIVE GRADE Grade 1 grade 3 Grade 5 group groups high resolution high resolution CT high-flow oxygen therapy Hospitalized HRCT Infection institutional review board Intention Invasive mechanical ventilation Ivermectin lung lobe mechanical ventilation morbidities nasal no evidence of noninvasive normal saline number objective outcome outcome assessor outcome assessors oxygen Oxygen therapy oxygen) Pakistan participant Patient patient recruitment patients with moderate PCR Physicians Placebo placebo group placebo-controlled positive pregnant women presence or absence primary care primary endpoints protocol radiological improvement randomisation randomised randomised controlled trial Randomized randomized clinical trial Randomly receive recorded Registered reported requiring supplemental oxygen Sample size SARS-CoV-2 SARS-CoV-2 clearance secondary endpoint seven-point scale severe respiratory syndrome severity Standard standard care status Study protocol Subcutaneous Ivermectin supplemental oxygen supplementary material symptomatic synergy Trial website Zinc
[DOI] 10.1186/s13063-021-05487-z PMC 바로가기 [Article Type] Letter

Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

영국 지역 사회에서 합병증의 위험이 높은 사람들의 Covid-19에 대한 흡입 부데소니드 (원칙) : 무작위, 제어, 오픈 라벨, 적응 형 플랫폼 시험

Randomized Controlled Trial

Published on 2021-09-042022-08-13
Journal: Lancet (London, England) [Category] MERS, SARS, 임상,

[키워드] absolute difference Adaptive platform trial Admission analysed assigned Bayesian credible interval Bayesian models BCI benefit Budesonide chance Community Comorbidities Complication complications COVID-19 COVID-19 in patient credible interval death Effectiveness Efficacy eligible Eligible participants Endpoint enrolment estimated rate finding funding greater hazard ratio high risk higher risk hospital Hospital admission Hospital admissions IMPROVE include individual inhaled budesonide inhaled budesonide reduce Innovation ISRCTN ISRCTN registry multi-arm multicentre Odds ratio Older Open-label other treatment other treatments outcome participant people with COVID-19 Platform trial primary analysis primary analysis population primary care Probability randomisation randomised Randomly receiving reducing Registered SARS-CoV-2-positive participant SARS-CoV-2-positive participants Serious Adverse Event Serious Adverse Events superiority criterion threshold Time to recovery Trial United Kingdom usual care usual care alone usual care group
[DOI] 10.1016/S0140-6736(21)01744-X PMC 바로가기 [Article Type] Randomized Controlled Trial

Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial

고위험 COVID-19 환자의 항바이러스 및 면역조절 인터페론-베타: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-09-032022-09-10
Journal: Trials [Category] 임상, 치료제,

[키워드] acting Acute respiratory failure acutely ill patient acutely ill patients addition Admission age allergy anamnesis antiretroviral Antiviral Antiviral treatment approach ARMS assigned Asthma Autoimmune disease AVPU being binding antibody Blinding block blocks blood pressure blood sample bridge calculated Care cartridge Chemotherapy chronic kidney diseases clinical assessment Clinical Center clinical centers Clinical deterioration clinical monitoring Clinical sign conducted Control control arm control group control patients Controlled COVID-19 COVID-19 symptoms crackles creatinine criteria cytokine Darmstadt Day death Dementia determined by diagnosed disease Disease progression dissemination dose Efficacy EGFR Elderly patient element eligible Eligible patients Endpoint enrolled enrolment EudraCT evaluate Evidence evidence of exclusion criteria expected experimental arm female following form Gender Germany Health heart rate High-dose HIV infection Hospitalized hospitalized patients hypersensitivity ICU identification number IFN IFN-β IFNβ immunomodulation immunomodulatory immunomodulatory property immunosuppressive Impaired impairing inclusion criteria increase in Infectious disease Infectious diseases Informed consent injected injection intensive care unit interferon Interferon-beta investigator involved kidney laboratory-confirmed SARS-CoV-2 infection Lazzaro Spallanzani less level of care Life expectancy low-dose male management mechanical ventilation mild COVID-19 symptom mild COVID-19 symptoms multiple sclerosis Nasopharyngeal swab nasopharyngeal swabs National Early Warning Score NEWS2 non-hospitalized patients normal range number objective Older open Open-label outcome oxygen oxygen saturation participant Patient patient identification patients patients treated PCR performed phase physical physician Presence primary endpoint proportion protocol provide Psychological pulse rales randomised randomised controlled trial randomization randomization system Randomized Randomly receive recruitment reducing reduction in Regional registration date relapsing renal function Respiratory failure respiratory rate responsible resulting risk Rome room air RT-PCR Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RT-PCR score Secondary objective Secondary objectives selected sequence severe COVID-19 severe depression severe disease specimen SpO2 Standard of care status stratified Stratified randomization Study protocol subcutaneously subject supervision supplemental oxygen supplementary material symptomatic temperature Toxicity treat Treatment treatment arm treatment group Trial Trial registration unique unit venous venous blood Version vital signs website Withdrawal worsening written Informed Consent
[DOI] 10.1186/s13063-021-05367-6 PMC 바로가기 [Article Type] Letter

Impacts of COVID-19 on essential health services in Tigray, Northern Ethiopia: A pre-post study

에티오피아 북부 티그레이의 필수 보건 서비스에 대한 Covid-19의 영향 : 사전 연구 연구

Research Article

Published on 2021-08-272022-09-10
Journal: PLoS ONE [Category] MERS, SARS, 치료기술, 치료제,

[키워드] addition Admissions agency Antiretroviral therapy approaches ART Blood Blood Bank Blood Transfusion calculated Cancer Cancer screening cardiovascular disease Care cervical cancer child health children Co-infection communicable disease communicable diseases country COVID COVID-19 COVID-19 pandemic CVD Effect enrolment Evidence expand FIVE focus Health Health care Health Service Health services HIV HIV testing Impact increase in International lead Local Malnutrition management moderate morbidity and mortality mother National Neonatal Non-communicable disease non-communicable diseases number of children nutrition outreach Patient proportions Result risk SAM screened Section significance level significant changes in significant decrease significant difference significant increase Stata version 14.0 Study design transfused Transmission Treatment vaccine dose was done was used
[DOI] 10.1371/journal.pone.0256330 PMC 바로가기 [Article Type] Research Article

Effect of COVID-19 on smoking cessation outcomes in a large primary care treatment programme: an observational study

Observational Study

Published on 2021-08-262022-10-05
Journal: BMJ Open [Category] SARS, 임상,

Through DNA sensors and hidden mitochondrial effects of SARS-CoV-2

Review

Published on 2021-08-232022-10-30
Journal: The Journal of Venomous Animals and Toxins Including Tropical Diseases [Category] COVID-19,

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

남아프리카에 HIV가 있거나없는 사람들의 SARS-COV-2에 대한 Chadox1 NCOV-19 (AZD1222) 백신의 안전성 및 면역 원성 : 무작위, 이중 맹검, 위약 대조, Phase 1B/2A 시험의 중간 분석

Clinical Trial

Published on 2021-08-172022-08-13
Journal: The Lancet. HIV [Category] MERS, SARS, 변종, 임상, 진단,

[키워드] 1:1 1B/2A trial 95% CI adverse event adverse events African Alanine alanine aminotranferase allocation concealment Antibody Response Antibody Units Antiretroviral therapy Asp614Gly wild-type AZD1222 B.1.351 baseline Beta Beta variant binding antibodies binding antibody unit booster booster response both groups ChAdOx1 ChAdOx1 nCov 19 ChAdOx1 nCoV-19 clinical COV005 criteria cross-reactive binding antibodies cross-reactive binding antibody cross-reactivity D614G demonstrated died domain dose double-blind elevated eligibility criteria enrolled enrolment Fever finding FIVE foundation full-length funding geometric mean geometric mean concentration GMC high responder high responders High-level binding antibody HIV HIV-negative hospital IgG responses immunogenicity in both groups increased risk individual individuals Innovation interim analysis Intervention less Medical Research Council Melinda Gate Melinda Gates n=36 nCoV neutralisation Neutralising activity outcome Pan participant Participants people with HIV person with HIV Placebo placebo-controlled plasma Primary immunogenicity analyses Primary immunogenicity analysis prime-boost regimen priming priming dose randomised Randomly reactogenicity receive Receptor-binding domain Registered registry responses responses against retained rising Safety SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens Serious Adverse Events seronegative seropositive serum IgG Seven severe COVID-19 South South Africa titre Trial unlikely Vaccine vaccine dose Viral Viral load wild-type wild-type Wuhan-1 Asp614Gly with HIV
[DOI] 10.1016/S2352-3018(21)00157-0 PMC 바로가기 [Article Type] Clinical Trial

Investigation of SARS-CoV-2 faecal shedding in the community: a prospective household cohort study (COVID-LIV) in the UK

지역 사회에서 SARS-Cov-2 Faecal Shedding의 조사 : 영국의 예비 가정 코호트 연구 (Covid-Liv)

Observational Study

Published on 2021-08-092022-09-10
Journal: BMC Infectious Diseases [Category] MERS, SARS, 임상, 치료기술,

[키워드] 95% CI 95% confidence interval addition All study participants asked Asymptomatic cohort study Community community transmission contribute COVID-19 demonstrated detect detected in stool determine disease enrolled enrolment Faecal shedding Gastrointestinal gastrointestinal symptoms hospitalised household transmission Households individual investigation Observational cohort study occurred participant Patient PCR positive Prevalence prevalence study Real-time PCR respiratory Respiratory samples Result SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2 virus Spread Stool Study participants supplementary material Swab swabbing tested Transmission unlikely with COVID-19
[DOI] 10.1186/s12879-021-06443-7 PMC 바로가기 [Article Type] Observational Study